T2 Biosystems Receives Delisting Notice from Nasdaq, Plans to Move to OTC MarketsLEXINGTON, Massachusetts–(BUSINESS WIRE)–T2 Biosystems, Inc. (NASDAQ: TTOO) announced today that it has received notice from the Nasdaq Stock Market LLC (“Nasdaq”) reg

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read T2 Biosystems’s 8K filing here.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.